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Thromboembolic and Bleeding Complications
in Patients With Mechanical
Heart Valve Prostheses
S.C. Cannegieter, MD; F.R. Rosendaal, MD; E. Briet, MD
Background Patients with mechanical heart valve prosthe-
ses may experience valve thrombosis and subsequent systemic
embolism for which they are treated with oral anticoagulant
therapy. It is essential to know reliable estimates of the risks
and benefits of this therapy in order to answer a number of
clinical questions rationally. We sought to obtain more precise
estimates of the risks and benefits by combining the data from
individual studies by using meta-analysis.
Methods and Results We searched for studies in which the
incidences were reported of embolic or bleeding Complications
in patients with mechanical heart valve prostheses. They were
collected from the Medline and Current Contents database
and by cross-references between 1970 and 1992. Since most
studies vary greatly in many respects, we used a number of
inclusion criteria, thus selecting comparable studies of accept-
able quality only. The influence of antithrombotic therapy,
valve position, and valve type was analyzed by univariate and
by multivariate analysis with Poisson regression techniques.
Forty-six studies were found, including 13 088 patients studied
for 53 647 patient-years. We found an incidence of major
embolism in the absence of antithrombotic therapy of 4 per
100 patient-years. With antiplatelet therapy this risk was 2.2
per 100 patient-years, and with cumarin therapy it was reduced
to l per 100 patient-years. This risk varied with the type and
the site of the prosthesis. A prosthesis in mitral position
increased the risk almost twice äs compared with the aortic
position. Tilting disc valves and bileaflet valves showed a lower
incidence of major embolism than caged ball valves. An
incidence of major bleeding was found in patients treated with
cumarin derivatives of 1.4 per 100 patient-years. The incidence
of bleeding became significantly higher with the addition of
antiplatelet therapy, although this did not decrease the risk of
thromboembolism any further.
Conclusions These data provide a reference for future
studies and give adequate risk estimates for clinical decision
making. (Circulation. 1994;89:635-641.)
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In March 1960, the first successful replacement of anaortic valve was performed by Harken.1 In thefollowing years, many modifications have been
made and new designs introduced to address specific
deficiencies in these early devices. Most modern pros-
theses now offer good durability and hemodynamic
characteristics. The main problem still remaining is the
thromboembolic potential of these valves.
Implantation of an artificial device places a large
foreign surface in contact with the bloodstream. Throm-
bus formation on the valve may be influenced — accord-
ing to Virchow's triad — by surface characteristics of the
prosthesis (material and design), blood flow (cardiac
Output, turbulence, and Stagnation), and characteristics
of the blood constituents of the patient (hypercoagula-
bility). Clinically, this may result in significant disrup-
tion of valve function, a life-threatening event. Likewise,
parts of the thrombus may embolize to peripheral
arterial sites. These emboli usually involve the central
nervous System, resulting in a spectrum of effects rang-
ing from transient to sometimes fatal events. To prevent
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these Complications, life-long oral anticoagulation ther-
apy is recommended in all patients.2 However, this
treatment introduces a risk of severe or fatal bleeding.3
In the past 20 years, many reports have been pub-
lished on the risks of thromboembolic and bleeding
Complications. Unfortunately, the reported results vary
greatly because of differences in patient selection, def-
initions of end points, methods of follow-up and statis-
tical analysis, and type, intensity, and efficacy of anti-
coagulation therapy.4 Besides, the quality of the reports
is often inadequate. McGoon5 examined 51 reports on
this subject and concluded that none of these gave
complete information. Consequently, from the Informa-
tion of the individual studies, it is hardly possible to
establish the risks of thromboembolism and bleeding
with any reliability. Assessing the influence of factors
such äs position and model of the valve is even more
difficult.
Many clinical questions cannot be answered ratio-
nally without reliable estimates of the risks and benefits
of oral anticoagulation: what is the optimal intensity of
anticoagulation for various groups of patients; what is
the risk of temporarily interrupting anticoagulation in
patients who have recurrent bleeding Complications or
in patients who require surgery; which patients should
receive bioprostheses instead of mechanical prostheses,
etc. In addition, it is important to know the extent of
these risks in the design of clinical trials in which the
optimal therapy is investigated.
We have set out to obtain reliable estimates of the
risks of thromboembolic and bleeding Complications in
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TABLE 1. Studies Included in This Review
Anticoagulation
None
Antiplatelet
Cumarin
Cumarin and antiplatelet
Valve Position
Aorta
Mitral
Both
Not stated/mix
Valve model
Starr-Edwards
Björk-Shiley
St Jude
Medtronic-Hall
Lillehei-Kaster
Omniscience
Omnicarbon
Smeloff-Cutter
Duromedics
Bicer
Not stated/mix
Patients
460
595
11 213
820
4679
1555
534
6320
821
5344
2011
1517
750
835
354
294
508
99
555
Patient-Years
1225
1226
49494
1702
24582
9618
2837
16610
1945
28468
6984
4711
4933
1743
555
1586
1064
93
1565
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40, 45-50
11,16,46,47,49,51-55
10-40
41-44
10, 12, 15-17, 25, 26, 30, 31, 34, 38-40, 45-50, 52-55
12,21,25,27,38
12,25,26,36
11, 13, 14, 18-20, 23, 24, 28, 29, 32, 33, 35, 37, 41-44, 51
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17, 19, 25-27, 30, 36, 38, 42, 51
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patients with mechanical heart valves to provide an
adequate basis for answering these questions. We com-
bined the data from individual studies by using meta-
analysis, a systematic and quantitative reviewing strate-
gy.6·7 To minimize the problems of variability between
studies caused by differences in methodological strength
or completeness of Information, we used rigorous inclu-
sion criteria.
Methods
Data Collection
We searched for original studies with data on the incidences
of thromboembolic complications, bleeding complications, or
both in patients with mechanical heart valve prostheses. These
were collected from the Medline and Current Contents data-
base and by cross-references. We initially selected all studies
published in English between 1985 and 1992. The reports were
only included if the following criteria were stated and met:
duration of follow-up; type of anticoagulation and number of
patients treated; possibility to discriminate, according to the
following definitions, between thrombosis (valve-related clot-
ting impairing the function of the valve, diagnosed at Operation
or autopsy); major embolism (causing death, residual neuro-
logical deficit, or peripheral ischemia requiring surgery); mi-
nor embolism (transient cerebral or peripheral ischemia);
major bleeding (intracranial bleeding, bleeding causing death
or necessitating hospitalization); minor bleeding (all other
bleeding); and results reported separately by model or position
of the valve or by type or intensity of anticoagulation therapy.
In addition to studies that did not fulflll these criteria,
reports were excluded that concerned selected patient groups
only (such äs children, elderly patients only, additional coro-
nary bypass surgery in all patients, etc); included bioprosthe-
ses without separate analysis of these valves; studied a patient
group already included in reports published later; and studied
triple valve replacement only.
In this set of studies (published after 1985), most patients
received cumarin therapy. Since we were interested in the risk
of thromboembolic complications in the absence of such
treatment, we extended our search to all studies published in
English after 1970 in which no anticoagulation therapy was
given or only antiplatelet treatment was given. The same
inclusion criteria were applied.
A standardized data form was used to extract Information
on position and type of the valve, type and level of anticoag-
ulation, number of patients and patient-years, and number of
complications for each report.
If a study contained Information on more than one series of
patients with differences in valve position, valve type, or type
of anticoagulation, these series were analyzed äs if they were
separate studies.
Statistical Analysis
We used two methods to obtain summary results: First,
averages of the results of the individual series, weighted by
study size, were calculated. Ninety-five percent confidence
intervals (CI) were calculated with the assumption of a
Poisson distribution of the outcome of interest.8 Second, since
valve position and valve type were not distributed equally over
the different anticoagulation groups, we performed a multi-
variate analysis by Poisson regression techniques.9 For in-
stance, in most studies in which no anticoagulation was given,
older valve types such äs Starr-Edwards were used, often in
aortic position. Analyzing these variables in a univariate way
may lead to confounded results. With multivariate analysis, it
is possible to determine the effect of one variable while the
other variables are adjusted for. Since studies were compared
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TABLE 3. Multivariate Analysis With Poisson Regression Techniques
Major Embolism
Rate Ratiof 95% Clt
Total Embolism
Rate Ratiof 95% C\t
No anticoagulation
Antiplatelet treatment
Cumarin+antiplatelet
Cumarin
Mitral Position
Aortic and mitral positions
Aortic position
Tilting disk valves
Bileaflet valves
Caged ball valves
3.7
1.9
1.3
1.0*
1.8
1.9
1.0*
0.7
0.6
1.0*
2.5-5.6
1 .3-2.9
0.9-2.0
1 .4-2.2
1.3-2.7
0.5-1.0
0.4-0.9
5.6
4.8
1.4
1.0*
2.4
1.9
1.0*
0.7
0.5
1.0*
4.2-7.5
3.8-6.0
1.0-1.8
2.0-2.8
1 .4-2.5
0.5-0.9
0.4-0.7
*Reference category.
flncidence rate ratlos for major and total embolisms are shown for different treatment regimens, valve positions,
and valve types. The rate ratio may be interpreted äs the risk relative to the reference category, with its
corresponding 95% confidence interval (Cl).
ΦΑ 95% Cl that does not include unity denotes statistical significance at the .05 level.
cidence of major embolism of 1.0 (95% Cl, 1.0 to 1.1)
per 100 patient-years with cumarin therapy compared
with the incidence of 4.0 (95% Cl, 2.9 to 5.2) without, äs
was found with univariate analysis (Table 2).
Antiplatelet therapy was associated with a twofold
higher risk of major embolism than cumarin therapy, äs
we also found in univariate analysis. Cumarin deriva-
tives combined with antiplatelet therapy did not appear
to be superior to cumarin therapy alone (the 95% Cl
includes l, the rate ratio of the reference group).
Position of the Valve
Unfortunately, in the studies in which no antithrom-
botic treatment or antiplatelet treatment only was given,
it was not possible to analyze separately for the aortic
and mitral positions with univariate analysis because in
most studies, either an aortic valve was used or the
position of the valve was not stated at all. However, in
the studies in which the patients were treated with
cumarin derivatives, the position of the valve was stated
often enough to calculate incidence rates for the differ-
ent valve positions (Table 4). The incidence rate of the
mitral valve compared with that of the aortic valve was
five times äs high for valve thrombosis and about 1.5
times äs high for embolism. With multivariate analysis,
the effect of the position of the valve was similar äs with
univariate analysis (Table 3), ie, a higher risk for the
mitral position.
Valve Model
We defined three broad categories of valve models:
the caged ball types (Starr-Edwards and Smeloff-Cut-
ter), the tilting disc valves (Björk-Shiley, Medtronic-
Hall, Lillehei-Kaster, Omniscience, Omnicarbon, and
Bicer), and bileaflet valves (St Jude and Duromedics).
In the studies in which no anticoagulation was given,
the most commonly used valve type was the Starr-
Edwards ball valve. No difference in the incidence of
either thrombosis or embolism was found between the
Starr-Edwards and other valve models (all in aortic
position). The same applied for the antiplatelet group.
In the cumarin treatment group, no differences between
the different valve types could be demonstrated.
However, using multivariate analysis to adjust for
other variables, we found a higher risk for the caged ball
valves compared with the tilting disk and bileaflet valves
(Table 3). In this analysis, we also included the studies
in which the position or the model of the valve was not
stated or in which a mixture was used. Since the
outcome of the analysis has no meaning for these
groups, these results are not reported. They had to be
included in the analysis, however, in order to use all
information on the other variables optimally.
We performed a subgroup analysis within the caged
ball valve studies to examine a possible difference
between cloth-covered and non-cloth-covered valves.
With multivariate analysis, we found a rate ratio of
TABLE 4. Incidence Rates of Valve Thrombosis and Major and Total Embolisms With
Cumarin Therapy: Effect of Valve Position
Incidence Rates per 100 Patient-Years (95% Confidence Intervals)
Valve Position Valve Thrombosis Major Embolism Total Embolism*
Aortic
Mitral
Both
0.1 (0.1-0.2)
0.5 (0.3-0.7)
0.4 (0.2-0.7)
0.8 (0.7-0.9)
1.3(1.1-1.5)
1.4(1.0-1.9)
1.1 (1.0-1.3)
2.7 (2.3-3.0)
2.1 (1.6-2.7)
*This category includes all reported incidences (valve thrombosis, major embolism, and minor
embolism).
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TABLE 5. Incidence Rates of Cerebral, Major, and Total Bleeding
Incidence Rates per 100 Patient-Years
(95% Confidence Intervals)
Anticoagulation
Antiplatelet
Cumarin
Antiplatelet and cumarin
Cerebral Bleeding
NDA*
0.5 (0.4-0.7)
NDA*
Major Bleeding
NDA*
1 .4 (1 .2-1 .5)
NDA*
Total Bleedingt
0.5(0.1-1.2)
1 .9 (1 .7-2.0)
4.6(3.1-6.4)
*NDA indicates no data available.
tThis category includes all reported incidences (cerebral bleeding, major bleeding, and minor
bleeding).
cloth-covered compared with non-cloth-covered valves
of 1.4 (95% CI, 0.6 to 3.2) for major embolism and a rate
ratio of 1.3 (95% CI, 0.8 to 3.2) for total embolism. No
clear difference could be demonstrated.
To eliminate a possible effect of the publication
period, the multivariate analysis was also performed
with the studies published after 1980 only. This led to
similar results (data not shown).
Bleeding
The incidence rates of cerebral, major, and total
bleeding are shown in Table 5. None of the reports in
the "no treatment" category reported the incidence of
bleeding. Placebo-controlled trials have never been
carried out in these patients, so data on the incidence of
bleeding in the absence of antithrombotic treatment are
lacking. In the reports of the antiplatelet studies, the
number of bleedings was not always stated. In the
studies in which it was, major bleeding could not be
analyzed separately.
Treatment with oral anticoagulation therapy gave rise
to an incidence of major bleeding of 1.4 per 100
patient-years (95% CI, 1.2 to 1.5). The addition of
antiplatelet treatment to cumarin derivatives appeared
to increase the bleeding risk: We found an incidence of
total bleeding of 4.6 per 100 patient-years (95% CI, 3.1
to 6.4), which was higher than that of cumarin therapy
only (this series of studies was too small to calculate the
incidence of major bleeding separately).
Mortality
In the studies in which no anticoagulation or anti-
platelet therapy was given, the late mortality was stated
only occasionally, so this could not be analyzed for these
groups.
The total late mortality (more than 30 days after valve
Implantation) in the studies in which cumarin therapy
was given was 4.6 per 100 patient-years (95% CI, 4.3 to
4.8). No difference in mortality was found accoiding to
valve position (aortic valve, 4.5 [95% CI, 4.2 to 4.9];
mitral, 4.6 [95% CI, 4.1 to 5.0]; and both valves, 4.8
[95% CI, 3.6 to 6.1] per 100 patient-years).
Discussion
Thromboembolism and anticoagulant-related bleed-
ing remain the most frequent complications of mechan-
ical heart valve prostheses.56 Many reports have been
published on the risks of these complications. However,
the reported results differ enormously, and the quality
of the studies is often inadequate.4·5 Therefore, from the
information of the individual studies, it is not possible to
answer many clinical questions rationally. This variabil-
ity results first of all from the lack of standardization of
definitions of complications. Of the 180 studies initially
selected, a distinction in minor, major, and lethal com-
plications could not be made in 39, which distinction is
of the utmost importance. Assessment of major events
that require hospitalization or cause death will be more
objective than assessment of minor events. Besides,
patients are inclined to forget transient events, espe-
cially when follow-up was retrospective or prospective,
with long intervals between contacting the patient. This
has been demonstrated recently by Bodnar and Horst-
kotte.57 Two publications give guidelines for reporting
valve-related complications58'59; surprisingly, neither ad-
vises distinguishing between minor and major embo-
lisms. We strongly recommend adding this distinction
when using these guidelines to increase the comparabil-
ity among the different studies. Other causes of incom-
parability are differences in patient selections, methods
of follow-up, and type and efficacy of anticoagulation
therapy.
To minimize the differences between the individual
studies and to select studies of similar quality, we used
a number of inclusion criteria äs stated in "Methods."
The Figure gives an overview of the incidences of major
embolism found in the included studies in which cu-
marin therapy was given with 95% CI. All valve types
and positions are included in the graph. Still, the
variability among these incidences is not äs large äs
described by Grunkemeier and London,4 who compared
a series of studies without the application of inclusion
criteria. Apparently, our inclusion criteria did improve
the comparability of the information and thus the
validity of the end result.
One study, however, Stands out: namely, the study
performed by Saour et al.37 They found an incidence
rate of major embolism of 3.85 per 100 patient-years,
which is much higher than the incidence rate reported
in any other study. Actually, this incidence rate is
similar to that usually found in the absence of treatment
(Table 2). We have no satisfactory explanation for this
finding.
We pooled the data from the included studies and
calculated the incidences of valve thrombosis, major
embolism, and total embolism. Because the most com-
parable and reliable figure is that of major embolism,
only this figure will be discussed.
Without anticoagulation, the risk of major embolism
is about 4 per 100 patient-years. Aspirin reduces the risk
of major embolism by about 40% compared with no
treatment but is only about half äs effective äs cumarin
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therapy. Dipyridamole does not appear to have any
effect on the prevention of thromboembolism either
alone or when given in combination with aspirin.
Cumarin therapy reduces the incidence of major
embolism by approximately 75% to an annual risk of
about 1%. The addition of antiplatelet treatment to
cumarin derivatives does not furtner decrease this risk.
In fact, there even appears to be a tendency toward an
increased risk. This may be due to the fact that these
patients possibly received less intense anticoagulant
therapy (because they were given antiplatelet therapy in
addition). These data leave little doubt about the ben-
efit of cumarin treatment in these patients, whereas that
of aspirin and dipyridamole is obviously not sufficient.
The risk of major bleeding caused by cumarin therapy
will be less than 1.4% annually, so the benefit of
cumarin therapy in these patients clearly outweighs the
risk. Still, it should be possible to minimize both embolic
and bleeding complications by optimalizing the inten-
sity of this treatment. It is reasonable to assume that the
risk of embolism decreases with higher intensities of
anticoagulation while the risk of bleeding increases. The
optimal intensity will be the level at which the sum of
both risks is minimal.60
To examine the possibility of fine-tuning this optimal
intensity according to site and type of the prosthesis, we
calculated the effect of these variables with univariate
and multivariate analyses. In patients who took cumarin
therapy, an apparent effect of the position of the valve
on the incidence of major embolism was found. This risk
is almost twofold higher with valves in the mitral
position than in the aortic position. The same result was
found with multivariate analysis, which means that this
effect is largely independent from other factors.
An effect of the valve model could not be established
with univariate analysis. With multivariate regression
analysis, however, we found that both tilting disc valves
and bileaflet valves showed a lower incidence of major
embolism than the caged ball valves. In a second
analysis, we excluded the studies that were published
before 1980. No major differences were found, so this
finding was not caused by the fact that the ball valves
were used mainly in the older studies. It may reflect a
real increased thrombogenicity of this valve model.
In most reports, basic information on the treatment
with oral anticoagulant therapy was lacking. In only five
studies was the target ränge stated äs International
Normalized Ratio (INR). In the other reports, the
target ränge was not stated at all or reported in such a
way that the INR could not be derived from the
provided information (except for one study in which the
target prothrombin time was mentioned and the type of
thromboplastin provided). Information on quality con-
trol of the treatment, eg, the percentage of prothrombin
times within the target ranges, was only sporadically
provided. Our summary results therefore could not be
related to anticoagulation levels. This considerable lack
of elementary information probably reflects the fact
that in many centers, anticoagulation monitoring has
not been considered äs important äs it should be. Thus,
efforts to reduce both embolic and bleeding complica-
tions to a minimum should not only include the search
for the optimal intensity but also and foremost, the
optimization of treatment monitoring.
An important clinical question that may be answered
more rationally on the basis of this study concerns the
risk of interrupting anticoagulation in patients with
recurrent bleeding complications or in patients who
require surgery. Without anticoagulation, we found a
risk of major embolism of about 4 per 100 patient-years
and a risk of valve thrombosis of 1.7 per 100 patient-
years. Although this is a high risk on a yearly basis, for
l day it will only be (4+1.7)/365=0.016% (ie, 1.6 in
10 000). Therefore, short Interruption of anticoagula-
tion may not be äs dangerous äs is often presumed. The
risk of severe damage to organs by bleeding when
anticoagulation is not fully interrupted is probably much
higher in these situations.
The aim of this study has been to provide a reference
for future studies and to give adequate estimates of risks
for clinical decision making. By using inclusion criteria,
we selected comparable information and could there-
fore calculate reliable and valid summary results. The
data show that cumarin treatment reduces the incidence
of major embolism in patients with mechanical heart
valves by approximately 75% from about 4% to 1%
yearly. This offsets the incidence of major bleeding of
1.4% yearly, induced by cumarin therapy. Obviously,
both risks will be influenced by the intensity of antico-
agulation therapy. The optimal intensity may differ
according to the type and site of the prosthesis, since
the risk of embolism is influenced by these variables.
To minimalize both embolic and bleeding complica-
tions in patients with mechanical heart valves, the
monitoring of cumarin treatment should be optimized,
and the optimal intensity should be sought.
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